Nasal shedding of vaccine viruses after immunization with a Russian-backbone live attenuated influenza vaccine in India.
developing countries
influenza
live attenuated influenza vaccine
pediatric
vaccine virus shedding
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
24
03
2023
received:
28
10
2022
accepted:
07
05
2023
medline:
30
6
2023
pubmed:
29
6
2023
entrez:
28
6
2023
Statut:
ppublish
Résumé
We present post-vaccination nasal shedding findings from the phase IV, community-based, triple-blinded RCT conducted to assess efficacy of trivalent LAIV and inactivated influenza vaccines in rural north India. Children aged 2-10 years received LAIV or intranasal placebo across 2015 and 2016, as per initial allocation. On days 2 and 4 post-vaccination, trained study nurses collected nasal swabs from randomly selected subset of trial participants based on operational feasibility, accounting for 10.0% and 11.4% of enrolled participants in 2015 and 2016, respectively. Swabs were collected in viral transport medium and transported under cold chain to laboratory for testing by reverse transcriptase real-time polymerase chain reaction. In year 1, on day 2 post-vaccination, 71.2% (74/104) of LAIV recipients shed at least one of vaccine virus strains compared to 42.3% (44/104) on day 4. During year 1, on day 2 post-vaccination, LAIV-A(H1N1)pdm09 was detected in nasal swabs of 12% LAIV recipients, LAIV-A(H3N2) in 41%, and LAIV-B in 59%. In year 2, virus shedding was substantially lower; 29.6% (32/108) of LAIV recipients shed one of the vaccine virus strains on day 2 compared to 21.3% on day 4 (23/108). At day 2 post-vaccination in year 1, two-thirds of LAIV recipients were shedding vaccine viruses. Shedding of vaccine viruses varied between strains and was lower in year 2. More research is needed to determine the reason for lower virus shedding and vaccine efficacy for LAIV-A(H1N1)pdm09.
Sections du résumé
BACKGROUND
We present post-vaccination nasal shedding findings from the phase IV, community-based, triple-blinded RCT conducted to assess efficacy of trivalent LAIV and inactivated influenza vaccines in rural north India.
METHODS
Children aged 2-10 years received LAIV or intranasal placebo across 2015 and 2016, as per initial allocation. On days 2 and 4 post-vaccination, trained study nurses collected nasal swabs from randomly selected subset of trial participants based on operational feasibility, accounting for 10.0% and 11.4% of enrolled participants in 2015 and 2016, respectively. Swabs were collected in viral transport medium and transported under cold chain to laboratory for testing by reverse transcriptase real-time polymerase chain reaction.
RESULTS
In year 1, on day 2 post-vaccination, 71.2% (74/104) of LAIV recipients shed at least one of vaccine virus strains compared to 42.3% (44/104) on day 4. During year 1, on day 2 post-vaccination, LAIV-A(H1N1)pdm09 was detected in nasal swabs of 12% LAIV recipients, LAIV-A(H3N2) in 41%, and LAIV-B in 59%. In year 2, virus shedding was substantially lower; 29.6% (32/108) of LAIV recipients shed one of the vaccine virus strains on day 2 compared to 21.3% on day 4 (23/108).
CONCLUSION
At day 2 post-vaccination in year 1, two-thirds of LAIV recipients were shedding vaccine viruses. Shedding of vaccine viruses varied between strains and was lower in year 2. More research is needed to determine the reason for lower virus shedding and vaccine efficacy for LAIV-A(H1N1)pdm09.
Identifiants
pubmed: 37380175
doi: 10.1111/irv.13149
pmc: PMC10293783
doi:
Substances chimiques
Influenza Vaccines
0
Vaccines, Attenuated
0
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13149Subventions
Organisme : NCIRD CDC HHS
ID : U01 IP000492
Pays : United States
Informations de copyright
© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
Vaccine. 2016 Sep 30;34(42):5066-5072
pubmed: 27613072
MMWR Recomm Rep. 2016 Aug 26;65(5):1-54
pubmed: 27560619
Pediatr Res. 2018 Jan;83(1-1):31-40
pubmed: 28945700
Lancet. 2011 Dec 3;378(9807):1917-30
pubmed: 22078723
Hum Vaccin Immunother. 2018 Mar 4;14(3):571-578
pubmed: 28933664
Vaccines (Basel). 2019 Jun 18;7(2):
pubmed: 31216759
Euro Surveill. 2016 Nov 10;21(45):
pubmed: 27918259
Viruses. 2018 Oct 15;10(10):
pubmed: 30326610
Clin Infect Dis. 2020 Jun 10;70(12):2505-2513
pubmed: 31642899
Clin Infect Dis. 2019 Aug 16;69(5):786-794
pubmed: 30481269
Lancet Respir Med. 2019 Aug;7(8):665-676
pubmed: 31235405
Lancet Glob Health. 2016 Dec;4(12):e955-e965
pubmed: 27746224
PLoS Pathog. 2014 Jan;10(1):e1003831
pubmed: 24391498
Lancet Glob Health. 2020 Apr;8(4):e497-e510
pubmed: 32087815
Lancet Glob Health. 2016 Dec;4(12):e879-e880
pubmed: 27746227
Vaccine. 2020 Jan 29;38(5):1001-1008
pubmed: 31796225
J Infect Dis. 2015 Feb 1;211(3):352-60
pubmed: 25165161
Clin Infect Dis. 2019 Aug 16;69(5):777-785
pubmed: 30481272
Expert Rev Vaccines. 2012 Nov;11(11):1293-303
pubmed: 23151111
Pediatr Infect Dis J. 2003 Jan;22(1):28-34
pubmed: 12544405
Viruses. 2019 Feb 22;11(2):
pubmed: 30813325
Lancet Glob Health. 2016 Dec;4(12):e946-e954
pubmed: 27746226
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):643-645
pubmed: 29879095
Expert Rev Vaccines. 2015 Mar;14(3):395-412
pubmed: 25555687
Vaccine. 2016 Oct 26;34(45):5436-5441
pubmed: 27593158
Vaccine. 2020 May 27;38(26):4209-4218
pubmed: 32376111
J Biomed Sci. 2020 Feb 14;27(1):33
pubmed: 32059697
Lancet Infect Dis. 2018 Jan;18(1):e25-e32
pubmed: 28780285
Vaccine X. 2019 Jun 19;2:100031
pubmed: 31384746
PLoS Med. 2021 Apr 29;18(4):e1003609
pubmed: 33914729